NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week announced that it has started a third Phase IIa trial for its anti-scarring treatment RXI-109.

RXI-109 is composed of siRNAs designed to inhibit connective tissue growth factor — a protein linked to wound healing and other fibrotic processes. It incorporates a proprietary self-delivering technology that enables cellular uptake of the RNAi molecules without the need for a delivery vehicle.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.